Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia

Next Previous
Search
Trial Profile

HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOVON 124 WM; HOVON 124 WM/ECWM-R2

Most Recent Events

  • 28 Jun 2024 This study has been completed in Belgium, according to European Clinical Trials Database record.
  • 19 Apr 2024 This study has been completed in Netherlands, according to European Clinical Trials Database record.
  • 10 Apr 2024 This study has been completed in Greece, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top